As of March 31, 2026, the distribution and sales of Forxiga\u00ae Tablets in Japan will be transferred from Ono Pharmaceutical Co., Ltd. to AstraZeneca, and joint promotion will end. The sales forecast for fiscal 2026 is 80 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4528-20260227-01.pdf","jir_short_summary":"As of March 31, 2026, the distribution and sales of Forxiga\u00ae Tablets in Japan will be transferred from Ono Pharmaceutical Co., Ltd. to AstraZeneca, and joint promotion will end. The sales forecast for fiscal 2026 is 80 billion yen.","jir_summary":"### Overview of Contract Termination\nOno Pharmaceutical Co., Ltd. has agreed to terminate the contract on March 31, 2026, with AstraZeneca K.K. and AstraZeneca UK Limited concerning the distribution, sales, and joint promotion of the selective SGLT2 inhibitor \"Forxiga\u00ae Tablets 5mg, 10mg\" in Japan, and to transfer distribution and sales to AstraZeneca. The contract was initially executed in December 2013, and since obtaining manufacturing and marketing approval in March 2014, Ono Pharmaceutical had been responsible for distribution and sales while both companies conducted promotional activities. However, reflecting changes in the market environment and following consultations, the decision to terminate the contract was made.\n\n### Future Outlook and Impact\nFollowing the termination of the contract, Ono Pharmaceutical\u2019s sales revenue from Forxiga will cease from April 1, 2026; however, the impact on the current fiscal year\u2019s performance is expected to be minor. The annual sales forecast for fiscal 2026 is 80 billion yen, and with the introduction of generic drugs, the effect on operating income for fiscal 2027 is assumed to be limited. Detailed information will be disclosed at the financial results announcement for the fiscal year ending March 2026. Both companies will cooperate in the transfer process and continue to promote stable supply and appropriate use.","jir_financial_highlights":"Sales Forecast of Forxiga\u00ae Tablets 5mg and 10mg for Fiscal Year Ending March 2026: 80 billion yen (Unknown)\nPeriod of Forxiga Sales Revenue Generation: No revenue from April 1, 2026 onwards (Unknown)\nContract Termination Date: March 31, 2026 (Unknown)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #BusinessUpdate, #JapaneseStocks","jir_key_figures":"Contract Termination Date: March 31, 2026\nForxiga Sales Forecast for Fiscal Year Ending March 2026: 80 billion yen\nForxiga Sales Revenue End Date: From April 1, 2026 onwards","jir_meta_title":"Ono Pharmaceutical to Transfer Forxiga\u00ae Tablet Sales in Japan to AstraZeneca by March 2026","jir_meta_description":"Ono Pharmaceutical will transfer the distribution and sales of the SGLT2 inhibitor Forxiga\u00ae Tablets in Japan to AstraZeneca as of March 31, 2026, ending joint promotion. The sales forecast for fiscal 2026 is 80 billion yen, with minimal expected performance impact.","jir_og_title":"Ono Pharmaceutical Transfers Forxiga\u00ae Sales in Japan to AstraZeneca","jir_og_description":"Ono Pharmaceutical will transfer the distribution and sales of Forxiga\u00ae Tablets in Japan to AstraZeneca at the end of March 2026 and terminate joint promotion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-32046","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n